Renee Stapleton, MD
Critical Care Medicine · Burlington, VTNPI 1689754657
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $9,742 of the $9,742 with a category attached, or 100.0%. Every reported general payment came from a single manufacturer, CSL Behring.
Across 7 payments — averaging $1391.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- CSL Behring$10K
Across 18 payments — averaging $9342.10 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Baxter Healthcare$121K
- Roche Products Limited$28K
- Astrazeneca UK Limited$19K
What the payments were for
- Speaking & faculty fees$9,742100%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| CSL Behring | 7 | $9,742 |
How this compares
Too few critical care medicine providers in Vermontto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent PenDupilumab | 33 | $161,748 |
| NucalaMepolizumab | 21 | $112,890 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 117 | $104,290 |
| Dupixent SyringeDupilumab | 15 | $55,766 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 24 | $16,106 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 25 | $16,042 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 14 | $3,539 |
| Roflumilast | 15 | $1,961 |
| Azithromycin | 72 | $1,686 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 39 | $1,564 |
| Montelukast Sodium | 16 | $168 |
| Olanzapine | 12 | $150 |
| Prednisone | 16 | $45 |
Paid to pharmacies, not to this prescriber.
Other critical care medicine in Burlington
- David KaminskyBurlington$21K
- John KlickBurlington$5K
- Katherine MensonBurlington$4K
- Katelin MorrissetteBurlington$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.